US · Healthcare · Biotechnology
EPS came in at -4.83 against a street estimate of -5.18 — a beat of 6.8%.
Analysts rate Jazz Pharmaceuticals PLC a strong buy (20 buy, 2 hold, 0 sell out of 22) with an average price target of $295.36.
CONFIDENT Jazz posted record $1.21B revenue (+16% YoY), raised 2026 guidance to $4.60–4.75B. Xywav outperformed on low-sodium durability; oncology surged 32%. Zanidatamab approval expected on/before Aug 25 PDUFA date. Q2 2026 No geographic breakdown disclosed; commentary focused on U.S. markets and select international FX headwinds in Q2. Analysts probed Xywav durability vs. upcoming orexin and generic oxybate, Epidiolex formulation/IP/clinical breadth, and zanidatamab breast cancer addressable market. Management stressed differentiation, clinical readiness, and early market penetration, deflecting long-term competition risks with combination-therapy and patient-support defensibility. 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.19% |
| FMR Inc | 7.10% |
| Vanguard Portfolio Management, LLC | 4.68% |
| Vanguard Capital Management, LLC | 4.21% |
| Capital World Investors | 4.16% |
| LSV Asset Management | 3.50% |
| Franklin Templeton Inc | 3.14% |
| State Street Corp | 3.08% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $1,243.0 million, up from $1,126.1 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $1,243.0 million, up 10% year over year from $1,126.1 million. • GAAP net loss was $483.4 million, | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Jazz Pharmaceuticals estimates a pre-tax charge of approximately $755 million in Q3 2026 for acquired in-process research and deve | 2026-10-26 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Jazz Pharmaceuticals’ Executive Vice President and Chief Commercial Officer, Samantha Pearce, intends to retire from her role. | 2026-10-09 |
| Material agreement · Q3 2026 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY – 8-K SUMMARY HEADLINE NUMBERS • Total outstanding term loan principal: $1,895,000,000 • Additional Tran | 2026-09-23 |
| Reg FD disclosure · Q3 2026 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition completed: Jazz Pharmaceuticals acquired Actio Bioscie | 2026-09-15 |
| Material agreement · Q3 2026 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY – 8-K SUMMARY HEADLINE NUMBERS • Jazz Pharmaceuticals completed a private offering of $1.25 billion in e | 2026-08-31 |
| Company announcement · Q3 2026 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics, revenue figures, or quantitative performance | 2026-08-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Actio Biosciences, now wholly-owned subsidiary Jazz Pharmaceuticals completed its acquisition of Actio Biosciences on September 15, 2026, with Actio becoming a wholly-owned subsidiary. The 8-K filing announces this transaction completion | 2026-09-15 |
| FDA approves Ziihera-containing regimens for HER2+ gastroesophageal adenocarcinoma Jazz Pharmaceuticals announced FDA approval of two new treatment regimens using Ziihera (zanidatamab-hrii) for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma | 2026-08-25 |
| Joint press release issued with Actio Biosciences regarding partnership Jazz Pharmaceuticals issued an 8-K filing on August 10, 2026, but the actual content of the announcement is not provided in this document excerpt. The filing only shows the formal structure | 2026-08-10 |
| Entered into merger agreement with Knight Acquisition Jazz Pharmaceuticals announced on August 10, 2026, that it is acquiring Actio Biosciences, Inc. for an upfront payment of $820 million, with potential additional milestone payments of up to | 2026-08-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jazz Pharmaceuticals PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.